Follow NDEWS on Twitter: @NDEWSnews

NDEWS ORIGINAL CONTENT

SNOW Interactive Dashboard

SNOW is an interactive dashboard presenting data from two sources across the United States: HIDTA and RADARS (poison control). The dashboard is updated regularly as new information becomes available. 

View the full dashboard here.

ARE THESE BEING USED IN YOUR AREA?

Complete our survey about this new substance.

New Substances Survey

NEW PSYCHOACTIVE SUBSTANCES (NPS)

NPS Discovery announcement of newly identified novel psychoactive substance in the United States

Late last week, NPS Discovery announced a newly identified NPS. Fluclotizolam is the newest NPS benzodiazepine to appear in a toxicology sample. Read the full report here.

IN THE NEWS

International law enforcement operation targeting opioid traffickers on the darknet

On October 26, 2021, the Department of Justice, through the Joint Criminal Opioid and Darknet Enforcement (JCODE) team, joined Europol to announce the results of Operation Dark HunTor, a coordinated international effort to disrupt opioid trafficking on Darknet markets. Operation Dark HunTor has resulted in the arrest of 150 alleged Darknet drug traffickers and others who engaged in tens of thousands of sales of illicit goods and services internationally. Read the full press release here.

NPS Discovery updates recommended scope testing for NPS based on Quarter 3 data

NPS Discovery released a new report regarding their Recommended Scope for NPS Testing in the United States based on data from Quarter 3 of 2021. Read the full recommended scope here.

Schedules of controlled substances: Placement of isotonitazene in Schedule I

This week, the Drug Enforcement Administration issued a final order to permanently place isotonitazene in Schedule I of the Controlled Substances Act, effective December 6, 2021. A temporary scheduling order for isotonitazene was issued in August 2020. Read the full announcement here.

RECENTLY PUBLISHED

The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era

In a study recently published in The American Journal of Drug and Alcohol Abuse, authors evaluated the effects of the SAMSHA exemption (allowing for an increase in methadone take-home doses), on methadone adherence and and OUD-related outcomes. Results showed that despite a near-doubling of take-home methadone doses during the COVID-19 exemption period, the increase in take-home doses was not associated with negative treatment outcomes in methadone-adherent clients. Read the full study here.

Follow NDEWS on Twitter: @NDEWSnews